title: Regulation of Complement and Contact System Activation via C1 Inhibitor Potentiation and Factor XIIa Activity Modulation by Sulfated Glycans - Structure-Activity Relationships.
abstract: The serpin C1 inhibitor (C1-INH) is the only regulator of classical complement activation as well as the major regulator of the contact system. Its importance is demonstrated by hereditary angioedema (HAE), a severe disease with potentially life-threatening attacks due to deficiency or dysfunction of C1-INH. C1-INH replacement is the therapy of choice in HAE. In addition, C1-INH showed to have beneficial effects in other diseases characterized by inappropriate complement and contact system activation. Due to some limitations of its clinical application, there is a need for improving the efficacy of therapeutically applied C1-INH or to enhance the activity of endogenous C1-INH. Given the known potentiating effect of heparin on C1-INH, sulfated glycans (SG) may be such candidates. The aim of this study was to characterize suitable SG by evaluating structure-activity relationships. For this, more than 40 structurally distinct SG were examined for their effects on C1-INH, C1s and FXIIa. The SG turned out to potentiate the C1s inhibition by C1-INH without any direct influence on C1s. Their potentiating activity proved to depend on their degree of sulfation, molecular mass as well as glycan structure. In contrast, the SG had no effect on the FXIIa inhibition by C1-INH, but structure-dependently modulated the activity of FXIIa. Among the tested SG, β-1,3-glucan sulfates with a Mr ≤ 10 000 were identified as most promising lead candidates for the development of a glycan-based C1-INH amplifier. In conclusion, the obtained information on structural characteristics of SG favoring C1-INH potentiation represent an useful elementary basis for the development of compounds improving the potency of C1-INH in diseases and clinical situations characterized by inappropriate activation of complement and contact system.
authors: Department of Pharmaceutical Biology, Pharmaceutical Institute, Christian-Albrechts-University of Kiel, Kiel, Schleswig-Holstein, Germany.
authors: Ann-Kathrin
authors: AK
authors: Schoenfeld
authors: Department of Pharmaceutical Biology, Pharmaceutical Institute, Christian-Albrechts-University of Kiel, Kiel, Schleswig-Holstein, Germany.
authors: Eric
authors: E
authors: Lahrsen
authors: Department of Pharmaceutical Biology, Pharmaceutical Institute, Christian-Albrechts-University of Kiel, Kiel, Schleswig-Holstein, Germany.
authors: Susanne
authors: S
authors: Alban
mesh_terms: D000464:Alginates / Q000737:chemistry / Q000378:metabolism; D003167:Complement Activation; D050718:Complement C1 Inhibitor Protein / Q000737:chemistry / Q000378:metabolism*; D016264:Dextran Sulfate / Q000737:chemistry / Q000378:metabolism; D057075:Enzyme Assays; D015956:Factor XIIa / Q000037:antagonists & inhibitors / Q000378:metabolism*; D020723:Glucuronic Acid / Q000737:chemistry / Q000378:metabolism; D006025:Glycosaminoglycans / Q000737:chemistry / Q000378:metabolism; D006497:Heparan Sulfate / Q000737:chemistry / Q000378:metabolism; D006603:Hexuronic Acids / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D011134:Polysaccharides / Q000737:chemistry / Q000378:metabolism*; D011485:Protein Binding; D013329:Structure-Activity Relationship; D013431:Sulfates / Q000737:chemistry; D047071:beta-Glucans / Q000737:chemistry / Q000378:metabolism
chemical_list: D000464:Alginates; D050718:Complement C1 Inhibitor Protein; D016264:Dextran Sulfate; D015956:Factor XIIa; D020723:Glucuronic Acid; D006025:Glycosaminoglycans; D006497:Heparan Sulfate; D006603:Hexuronic Acids; D011134:Polysaccharides; D013431:Sulfates; D047071:beta-Glucans; C033363:beta-1,3-glucan